REPAIR Is Trying To Fix The Antibiotic Gap Left By Industry

As large biopharmaceutical companies continue to exit antibacterial R&D, investments by Novo Holding’s REPAIR Impact Fund and grants from CARB-X can push forward novel therapies for drug-resistant microbial infections.

Aleks Engel of Novo Holdings
Novo Holdings Partner Aleks Engel

While the demand for discovery and development of novel therapies to address drug-resistant infections has been clearly elucidated again and again, the big biopharmaceutical industry players continue to pull out – but it remains to be seen whether new efforts to drive early-stage R&D can fill the gap.

Despite regulatory incentives like the GAIN (Generating Antibiotic Incentives Now) provisions the US FDA introduced in 2012, the antimicrobial resistance...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Anti-infective

More from Therapeutic Category